Arcturus Therapeutics Holdings ROA 2012-2021 | ARCT

Current and historical return on assets (ROA) values for Arcturus Therapeutics Holdings (ARCT) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
Arcturus Therapeutics Holdings ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2021-06-30 $-0.16B $0.45B -37.71%
2021-03-31 $-0.12B $0.48B -33.01%
2020-12-31 $-0.07B $0.48B -28.21%
2020-09-30 $-0.05B $0.32B -33.17%
2020-06-30 $-0.04B $0.15B -38.87%
2020-03-31 $-0.03B $0.07B -37.18%
2019-12-31 $-0.03B $0.08B -36.62%
2019-09-30 $-0.02B $0.09B -26.02%
2019-06-30 $-0.01B $0.07B -26.53%
2019-03-31 $-0.02B $0.04B -52.07%
2018-12-31 $-0.02B $0.04B -70.40%
2018-09-30 $-0.02B $0.04B -72.18%
2018-06-30 $-0.02B $0.04B -67.15%
2018-03-31 $-0.01B $0.00B -41.48%
2017-12-31 $-0.01B $0.05B -24.31%
2017-09-30 $0.01B $0.04B 25.17%
2017-06-30 $0.00B $0.04B 10.13%
2017-03-31 $-0.00B $0.05B -2.23%
2016-12-31 $-0.00B $0.01B -4.00%
2016-09-30 $-0.02B $0.06B -37.21%
2016-06-30 $-0.02B $0.06B -33.33%
2016-03-31 $-0.02B $0.07B -34.70%
2015-12-31 $-0.02B $0.07B -38.58%
2015-09-30 $-0.02B $0.04B -57.14%
2015-06-30 $-0.03B $0.04B -77.14%
2015-03-31 $-0.03B $0.05B -86.96%
2014-12-31 $-0.03B $0.02B -94.96%
2014-09-30 $-0.03B $0.03B -76.65%
2014-06-30 $-0.03B $0.04B -64.10%
2014-03-31 $-0.02B $0.05B -52.17%
2013-12-31 $-0.01B $0.05B -43.48%
2013-06-30 $-0.00B $0.02B -18.18%
2013-03-31 $0.00B $0.00B nan%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.172B $0.010B
Arcturus Therapeutics Ltd. is a preclinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of RNA medicines using proprietary lipid-mediated delivery system LUNAR(TM) and UNA Oligomer chemistry technologies. Arcturus Therapeutics Ltd, formerly known as Alcobra Ltd, is based in San Diego, CA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76